{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T13:06:51Z","timestamp":1698325611860},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The present study aimed to analyze treatment outcomes after induction chemotherapy followed by chemoradiotherapy (CRT) using volumetric-modulated arc therapy (VMAT) in patients with stage IVA-B oropharyngeal cancer (OPC) or hypopharyngeal cancer (HPC), with long-term observation, including examination of larynx preservation. A total of 60 patients with stage IVA-B OPC or HPC, who underwent induction TPF chemotherapy (a combination regimen consisting of docetaxel, cisplatin, and 5-fluorouracil) followed by CRT using VMAT were analyzed. Overall survival (OS), progression-free survival (PFS), laryngoesophageal dysfunction-free survival (LEDFS), and locoregional control (LRC) were calculated and compared. Univariate and multivariate analyses were performed to determine statistical differences in OS and LEDFS. The median follow-up period at the time of evaluation was 61\u00a0months. Twenty-six (43%) patients had OPC and 34 (57%) had HPC. The 5-year OS, PFS, LEDFS, and LRC rates were 57%, 52%, 52%, and 68%, respectively. Response to TPF therapy was the only significant predictive factor of OS and LEDFS in multivariate analyses. Regarding long-term toxicities, grade\u00a0\u2265\u00a02 late toxicities accounted for 15%. No patients experienced grade\u00a0\u2265\u00a03 xerostomia, and 5% of all patients developed grade 3 dysphagia. With long-term observation, the OS, PFS, and LEDFS rates were relatively good, and the incidence of late toxicities was low. TPF followed by CRT using VMAT was feasible and more effective in those who responded to induction chemotherapy.<\/jats:p>","DOI":"10.1093\/jrr\/rraa033","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T12:23:32Z","timestamp":1589286212000},"page":"554-562","source":"Crossref","is-referenced-by-count":1,"title":["Long-term outcomes of induction chemotherapy followed by chemoradiotherapy using volumetric-modulated arc therapy as an organ preservation approach in patients with stage IVA-B oropharyngeal or hypopharyngeal cancers"],"prefix":"10.1093","volume":"61","author":[{"given":"Katsumaro","family":"Kubo","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kenjo","sequence":"first","affiliation":[{"name":"Hiroshima High-Precision Radiotherapy Cancer Center, 2-2 Futabanosato Higashi-ku Hiroshima-shi, Hiroshima 732-0057, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuki","family":"Imano","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuno","family":"Nishibuchi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kawahara","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Ueda","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachio","family":"Takeno","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Nagata","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hiroshima University Hospital, 1-2-3 Kasumi Minami-ku Hiroshima-shi, Hiroshima 734-8553, Japan"},{"name":"Hiroshima High-Precision Radiotherapy Cancer Center, 2-2 Futabanosato Higashi-ku Hiroshima-shi, Hiroshima 732-0057, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"2020070608041295700_ref1","volume-title":"Head and Neck Cancers version 1","author":"National Comprehensive Cancer Network Inc NCCN Clinical Practice Guidelines in Oncology","year":"2020"},{"key":"2020070608041295700_ref2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"key":"2020070608041295700_ref3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10147-014-0726-y","article-title":"Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma","volume":"20","author":"Mizumachi","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2020070608041295700_ref4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/jjco\/hyv216","article-title":"Retrospective analysis of the clinical efficacy of definitive chemoradiotherapy for patients with hypopharyngeal cancer","volume":"46","author":"Takehana","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"2020070608041295700_ref5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jjco\/hyx115","article-title":"Chemo-selection with docetaxel, cisplatin and 5-fluorouracil (TPF) regimen followed by radiation therapy or surgery for pharyngeal and laryngeal carcinoma","volume":"47","author":"Matoba","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"2020070608041295700_ref6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10147-019-01418-w","article-title":"Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer","volume":"24","author":"Okano","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"2020070608041295700_ref7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fonc.2019.00006","article-title":"A multicenter phase ii trial of docetaxel, cisplatin, and cetuximab (TPEx) followed by cetuximab and concurrent radiotherapy for patients with local advanced squamous cell carcinoma of the head and neck (CSPOR HN01: ECRIPS study)","volume":"9","author":"Zenda","year":"2019","journal-title":"Front Oncol"},{"key":"2020070608041295700_ref8","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/cam4.2852","article-title":"A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck","volume":"9","author":"Enokida","year":"2020","journal-title":"Cancer Med"},{"key":"2020070608041295700_ref9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ijrobp.2008.10.047","article-title":"Larynx preservation clinical trial design: Key issues and recommendations-a consensus panel summary","volume":"73","author":"Lefebvre","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020070608041295700_ref10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2020070608041295700_ref11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijrobp.2008.04.048","article-title":"Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer","volume":"73","author":"Caudell","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2020070608041295700_ref12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(10)70279-5","article-title":"Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomised phase 3 trial","volume":"12","author":"Lorch","year":"2011","journal-title":"Lancet Oncol"},{"key":"2020070608041295700_ref13","article-title":"Long-term results of a multicenter randomized phase III trial of induction chemotherapy with Cisplatin, 5-fluorouracil, \u00b1 Docetaxel for larynx preservation","volume":"108","author":"Janoray","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2020070608041295700_ref14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/djn460","article-title":"Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy","volume":"101","author":"Lefebvre","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2020070608041295700_ref15","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1002\/cncr.26066","article-title":"Examination of laryngoesophageal dysfunction-free survival as an endpoint in nonsurgical treatment of squamous cell carcinomas of the larynx and hypopharynx","volume":"117","author":"Caudell","year":"2011","journal-title":"Cancer"},{"key":"2020070608041295700_ref16","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.21873\/anticanres.11269","article-title":"Laryngo-esophageal dysfunction-free survival in a preservation protocol for T3 laryngeal squamous-cell carcinoma","volume":"36","author":"Gorphe","year":"2016","journal-title":"Anticancer Res"},{"key":"2020070608041295700_ref17","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/lary.26425","article-title":"Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy","volume":"127","author":"Gorphe","year":"2017","journal-title":"Laryngoscope"},{"key":"2020070608041295700_ref18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3389\/fonc.2019.00625","article-title":"Laryngeal preservation approaches: Considerations for new selection criteria based on the DeLOS-II trial","volume":"9","author":"Dietz","year":"2019","journal-title":"Front Oncol"},{"key":"2020070608041295700_ref19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1288\/00005537-199504000-00012","article-title":"Squamous cell carcinoma of the pyriform sinus: A nonrandomized comparison of therapeutic modalities and long-term results","volume":"105","author":"Spector","year":"1995","journal-title":"Laryngoscope"},{"key":"2020070608041295700_ref20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hed.2890100103","article-title":"Squamous cell carcinoma of the pyriform sinus: Retrospective study of 351 cases treated at the Institut Gustave-Roussy","volume":"10","author":"Vandenbrouck","year":"1987","journal-title":"Head Neck Surg"},{"key":"2020070608041295700_ref21","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/cncr.23889","article-title":"African American and poor patients have a dramatically worse prognosis for head and neck cancer: An examination of 20,915 patients","volume":"113","author":"Molina","year":"2008","journal-title":"Cancer"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jrr\/article-pdf\/61\/4\/554\/33466511\/rraa033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jrr\/article-pdf\/61\/4\/554\/33466511\/rraa033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T12:04:36Z","timestamp":1594037076000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/61\/4\/554\/5858247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,6,17]]},"published-print":{"date-parts":[[2020,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rraa033","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,6,17]]}}}